glp-1 reviews oral Variable weight-loss and cardiovascular benefits were seen with drugs in a systematic review and network meta-analysis, but effects on quality of life were less clear. https://www.medpagetoday.com/primarycare/obesity/122142 Oral GLP-1 Drugs: How the

Still, insurance coverage and cost considerations mean both drugs remain relevant, and patient-centred conversations about therapy choice are critical. GLP-1s beyond weight loss as multi-system therapies Liver disease and metabolic steatohepatitis Non-alcoholic fatty liver disease (NAFLD) and the more severe metabolic dysfunction-associated steatohepatitis (MASH) have few effective pharmacologic treatments

Semaglutide physiologically mimics the function of endogenous GLP-1 hormone, promoting insulin secretion and suppressing glucagon s

When blood sugar drops, glucagon tells the liver to release stored glucose

Similar trials are assessing GLP-1RAs in overweight patients with IBD (110), in UC (NCT06937086), and exploring dual GLP-1/GIP agonists like Zepbound as adjunctive therapies (NCT06774079) (112)

Gastric banding was associated with lower migraine frequency, duration, pain, and medication use during migraine attacks

J., Rosenstock, J., et al